Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD) represent an important differential diagnostic problem in clinical practice. The identification for new biomarkers that would help establishing the diagnosis and primary cause of the dementia is therefore highly relevant. The aim of this study was to investigate the diagnostic accuracy of three potential CSF biomarkers, total tau protein (t-tau), tau protein phosphorylated at threonine 181 (p-tau181), and tau protein phosphorylated at serine 199 (p-tau199) in the differential diagnosis of AD and FTLD patients in relatively young age groups. The concentrations of the three CSF biomarkers were measured in 25 FTLD patients, 27 AD patients, and 25 non-demented (ND) subjects. The CSF concentrations of all three markers were significantly higher in AD than in FTLD cases (p < 0.001) or ND controls (p < 0.001). No difference was observed in FTLD compared to the ND group, except for p-tau181 (p = 0.028). When sensitivity was set at 85% or higher, specificity in differentiation between FTLD and AD patients reached 40% for t-tau, 37.5% for p-tau181 and 56% for p-tau199. Improvement of the diagnostic accuracy upon logistic regression analysis with t-tau and p-tau199 as independent variables showed that 22 out of 25 FTLD patients could be correctly classified. In conclusion, none of the markers per se fulfilled the criteria for the "ideal" marker (sensitivity and specificity higher than 85%). However, combination of t-tau and p-tau199 classified correctly 88% of FTLD patients, thus largely satisfying practical requirements.
From a clinical standpoint, Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD) may be distinguished by a combination of clinical criteria and neuroimaging. However, in younger patients with mild cognitive deficits, it is sometimes difficult to classify patients based only on clinical findings, probably due to overlap of cognitive deficits with prominent executive and behavioral dysfunction, apraxia, and language disorders found in young AD patients [1] . Because of this overlap, it is crucially important to find new diagnostic tools to help clinicians to make an early and accurate diagnosis of a primary dementia. Previous studies on the diagnostic value of CSF total tau (t-tau) and phosphorylated tau (p-tau) proteins in differential diagnosis of early-onset AD and FTLD are variable. This is partly due to the wide range of tau protein concentrations found in postmortem brains of FTLD patients [2] [3] [4] , but also due to large differences in age between the two groups [5] . To date, only few studies have evaluated CSF biomarkers between agematched AD and FTLD patients [6] [7] [8] and none evaluated CSF p-tau199. The aim of our study was to investigate the diagnostic value of total tau protein (t-tau), tau protein phosphorylated at threonine 181 (p-tau181) and tau protein phosphorylated at serine 199 (p-tau199) in agematched AD and FTLD patients.
Materials and Methods

Subjects
A total of 52 patients were recruited in this study; 27 patients with probable AD (according to NINCDS-ADRDA criteria) [9] , 25 patients with FTLD (21 with behavioural variant of FTLD and 4 with progressive non-fluent aphasia (PNFA); according to Neary's criteria [10] ). Additionally, 25 cognitively healthy individuals were included as a non-demented (ND) group presenting with non-progressive (monitored over a period of one year) subjective memory problems; cognitively healthy individuals for whom a lumbar puncture was indicated during regular diagnostic or therapeutic workup; MMSE score of 27 or higher, absence of objective memory or other cognitive deficits; absence of neurological, psychiatric, malignant and multisystemic diseases that may influence cognitive functioning, no psychotropic drugs (even though no influence of psychotropic drugs intake on t-tau concentration in CSF has been reported [11]) or intake of drugs for dementia (e.g., acetylcholinesterase inhibitors). Patients and ND subjects were recruited in three tertiary medical centres: Department of Neurology, UHC Zagreb, Croatia (15 AD and 12 FTLD patients and 23 ND subjects), University Department of Psychiatry, Psychiatric Hospital Vrapce, Zagreb, Croatia (1 AD and 1 FTLD patient), and Department of Neurology, UHC Grosshadern, Ludwig-Maximilians Universität, Munich, Germany (11 AD and 12 FTLD patients and 2 ND subjects). Exclusion criteria for AD and FTLD groups were non-specified and "mixed" dementia cases, primary psychiatric illnesses (e.g., psychosis or depression), history of chronic
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alcohol abuse, other neurological illnesses that may cause cognitive decay (e.g., multiple sclerosis, normal pressure hydrocephalus, tumors or infections of the central nervous system), secondary causes of cognitive deficits (e.g., hypothyroidism), multisystem diseases, and use of specific therapy for dementia (e.g., acetylcholinesterase inhibitors).
Methods
All patients and ND subjects underwent a standard investigation protocol consisting of general and neurological examination, neuropsychological testing, routine blood tests (including thyroid function, levels of vitamin B12, folic acid, VDRL), ECG, chest X-rays, ocular fundus examination, EEG, and neuroimaging (CT or MRI scan of the brain 
CSF sampling and analysis
Lumbar puncture was performed by a routine protocol (performed in the L3/L4 or L4/L5 intervertebral space, between 9 a.m. and 11 a.m., after 12 hours of fasting and 30 minutes of walking before the procedure, sample volume of 4-5 ml). CSF samples were collected in propylene tubes. A small volume of CSF was centrifuged for 10 minutes at 10,000 g, and 50 and 100 μl aliquots of the remaining supernatant were immediately frozen at -80 o C for later t-tau, p-tau181, and p-tau199 protein analysis. The majority of the sample volume was used for analysis of routine biochemical parameters (leukocyte and erythrocyte cell count, glucose, lactate, total protein concentration, IgG index, TPHA). Samples with erythrocyte cell count higher than 500/µl were excluded from the analysis. CSF analysis of the three biomarkers was performed in the Laboratory for Developmental Neuropathology of the Croatian Institute for Brain Research, Zagreb, using enzyme-linked immunosorbent assay (ELISA). CSF t-tau and p-tau199 levels were analyzed using Biosource International (Camarillo, CA, USA) ELISA kits, whereas levels of t-tau were determined using the Innotest hTau-Ag ELISA kit (Innogenetics, Ghent, Belgium). All tests were carried-out according to the manufacturers' protocols using an ELISA reader (model 680 Series; Biorad Laboratories, Hercules, USA) and automatic washer (model PW 40; Biorad Laboratories, Hercules, USA).
Statistical analysis
Clinical parameters and values of CSF t-tau, p-tau181, and p-tau199 were presented as means ± standard deviations as well as medians with 25th and 75th percentiles and interquartile ranges depending whether values were normally distributed or not. A KolmogorovSmirnov test was used to assess regularity of distribution for each parameter. Nonparametric analyses (Kruskal-Wallis followed by MannWhitney U test) were used to compare medians of t-tau, p-tau181 and p-tau199. Additionally, t-tests were performed for comparison of clinical data among the groups and statistical significances were compared to those of MannWhitney U test. Differences in gender among groups were assessed by χ 2 test. ROC (receiver operating characteristic) curves were drawn to assess diagnostic value of CSF markers in differentiation of the groups. Cut-off levels of all of the markers used in the study were derived from the ROC curve analysis, when the product of sensitivity and specificity reached maximum. Additionally, specificity of a marker was assessed when the sensitivity was set above 85%. Sensitivity and specificity were given with respective 95% CI. Additionally, areas under the curve (AUC) were calculated as an indicator of test accuracy. Correlations between age, MMSE score, t-tau, p-tau181, and p-tau199 in each group were assessed by calculating Spearman's rank correlation coefficients (r s ). For differentiation of AD and FTLD group, a logistic regression analysis with backward stepwise selection was used to assess impact of each variable on the diagnosis. Statistical analysis was performed using SPSS v.12.0.1. P values less than 0.05 were considered statistically significant.
results
Study cohort
A total of 77 patients and ND subjects were included in the study. Among them, there were 27 patients with probable AD, 25 patients with FTLD and 25 ND subjects. Demographic data of the subjects included in the study are presented in Table 1 . There was no significant difference between AD and FTLD group in age, while both AD and FTLD patients were significantly older then ND subjects at the time of lumbar puncture. Since there was no correlation between age and each CSF biomarker, lower mean age of ND subjects was not significant for interpretation of the results. Additionally, there was no significant difference in gender distribution (χ 2 = 0,695, df = 2, p > 0.05) and MMSE score among groups. Due to inclusion criteria for ND subjects (MMSE 27 or more), significant difference of MMSE score between groups of patients (AD and FTLD) and ND subjects was expected.
6.2. CSF biomarker levels, sensitivities and specificities of CSF biomarkers CSF levels of t-tau, p-tau181, and p-tau199 are presented in Table 1 (with values expressed as medians with 25 th and 75 th percentile and interquartile range) and graphically in Figures 1-3 . The median levels of each biomarker were significantly higher in AD versus FTLD group and ND subjects, whereas only p-tau181 reached statistical significance (p = 0.028) for differentiation of FTLD and ND subjects. Sensitivity and specificity levels, cut-off values, AUC and p-values for paired comparisons (AD versus FTLD) of a single as well as a combination of markers are shown in Table 2 . Specificity levels of single or a combination of markers were measured with sensitivity set at 85% or higher (Consensus Report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease [12] , later in the text "criteria of the working group"). The following markers or combination of markers reached statistical significance and accuracy (according to the AUC values) in differentiating patients with AD and FTLD: t-tau, p-tau181, p-tau199, sum of p-tau181 and p-tau199, and product of the three biomarkers. None of the markers or combination of markers fulfilled criteria of the working group, meaning none reached both specificity and sensitivity 85% or higher. P-tau199, product of all three biomarkers and subtraction of p-tau181 and p-tau199 were the closest to the ideal biomarker with specificity levels of 56%, 54.2%, and 50% respectively. At the same time specificity of t-tau was 40% and p-tau181 surprisingly low (37.5%). On the basis of ROC analysis, cut-off values for the three biomarkers were 500 pg/ml for t-tau, 63.45 pg/ ml for p-tau181, and 30,3 pg/ml for p-tau199.
Correlation of clinical and demographic data
Spearman's rank correlation coefficients among the three markers in each group of patients or ND subjects are shown in Table 3 . In AD and FTLD cases, statistically significant positive correlation between t-tau and p-tau181 was found (r = 0.570 for AD, r = 0.694 for FTLD). In ND subjects, no correlation was found among the markers. Additionally, correlation between the CSF biomarkers and other clinical parameters (gender, age at the time of lumbar puncture, and MMSE score) in each group of patients and ND subjects was calculated. Significant correlations are shown in the last column of Table 3 . There was a significant negative correlation between p-tau199 and MMSE score in the ND group (r = -0.516, p = 0.01). None of the clinical or laboratory parameters in either patients or controls showed statistically significant gender preponderance.
Combination of clinical data and values of CSF biomarkers
Six predictor variables (gender, age, MMSE score, t-tau, p-tau181, p-tau199) were selected for logistic regression analysis in order to predict diagnosis of AD. Good predictors for AD were t-tau > 500 pg/ml (OR = 18-37), p-tau181 > 63.45 pg/ml (OR = 11-31), and p-tau 199 > 30. (25,98 -34,85) AD = Alzheimer's disease, FTLD = frontotemporal dementia, ND = non-demented controls, MMSE = Mini Mental Status Examination, T-tau = total tau, P-tau181 = tau phosphorylated at threonine 181, P-tau199 = tau phosphorylated at serine 199, * p<0.001 vs. AD, # p<0.003 vs. AD, ¶ p = 0.028 vs. NC
discussion
In this study we evaluated three potential CSF biomarkers (t-tau, p-tau181, and p-tau199) in the differential diagnosis of AD and FTLD. CSF concentrations of these biomarkers were significantly higher in AD than in FTLD patients (p < 0.001) or ND group (p < 0.001). No difference was observed between FTLD and ND group, except for p-tau181 (p = 0.028). In this respect, results for t-tau and p-tau181 match previously published data [7, 8, 13] . There are two limitations of this study: the relatively small number of patients/individuals included in the study and the absence of postmortem histopathological confirmation of diagnosis. These factors might explain the high variance of our data. However, the lack of histopathological confirmation is compensated by uniformity of diagnostic procedures, detailed neuropsychological assessment, and longer clinical follow-up of our patient series, which may in turn minimize the relatively lower specificity of NINCDS-ADRDA criteria.
Lower concentrations of total and phosphorylated tau in CSF in FTLD compared to AD group of patients can be explained in a number of ways. First, due to its capture in chromatolytic balloon cells and Pick's bodies (as demonstrated in patients with corticobasal degeneration [15] ), migration of tau protein from neurons to extracellular space becomes inadequate. Second, heterogeneity of FTLD pathology with presence of tau-, but also ubiquitin-positive cases as well as cases lacking distinctive histopathology, may explain lower mean concentrations of tau in FTLD [3, 4] . Different localization of the degenerative process in AD and FTLD is also likely [15, 16] . The higher levels of CSF t-tau and p-tau181 in AD compared to FTLD might be partly explained by a positive correlation between CSF t-tau and number of NFT [17] . Also, mildly increased CSF levels of t-tau and p-tau181 were previously reported in FTLD [18, 19] . Interestingly, relatively higher levels of CSF t-tau and p-tau181 were found even when AD was compared to FTLD with tau mutation [20, 21] . Therefore, the difference is presumably due to more extensive neurodegeneration in AD and not neurofibrillary pathology alone, meaning that the presence of tau pathology in brains of FTLD patients does not necessarily imply, as thought before [22] , higher CSF levels of t-tau. In our study, levels of t-tau and p-tau181 were above cut-off values in one PNFA patient, while in the remaining three PNFA patients concentrations of all three biomarkers were bellow cut-off levels. Additionally, in only one out of 25 FTLD patients, all three markers were above cut-off levels (a finding typical in AD patients).
Despite significantly higher levels of all three biomarkers in AD compared to FTLD group, none fulfilled the criteria for an ideal marker according to the report of working group for biomarkers (sensitivity more then 85% and specificity between 75-85% or more) [12] . The closest marker to fulfill criteria was p-tau199 with sensitivity of 92.6% and specificity of 56% and high AUC (0.801). Sensitivity / specificity was 85.2% / 40% for t-tau and unexpectedly low (87% / 37.5%) for p-tau181. Low specificity (lower than ideal) of each CSF biomarker resulted in overlapping of values between groups. In our study, t-tau level was above cut-off value (>500 pg/ml) in 4 out of 25 FTLD patients. Additionally, concentrations of p-tau181 and p-tau199 were above cut-off values in 7 and 10 FTLD patients, respectively. Lower specificity of CSF markers in this study was primarily caused by false-positive values in FTLD patients, and less by false-negative values in AD patients (6/27 for t-tau, 5/27 for p-tau181, and 2/27 for p-tau199). High percentage of false-positive findings in FTLD patients could partially be explained by the fact that almost 15-33% of FTLD patients are ultimately diagnosed as AD at autopsy [23] .
Low specificity of current AD (NINCDS-ADRDA) criteria [24] necessitates new biomarkers that would allow adequate antemortem differentiation of primary dementias. To date, many CSF biomarkers (Aß42, t-tau, different phospho-tau epitopes, neurofilament proteins, GAP-43, isoprostane, etc.) have been investigated for the differential diagnosis of AD and FTLD. So far, the best accuracy was reached by using phosphorylated tau isoforms, especially in combination with other CSF biomarkers [7, 25, 26] . Although promising, none of the markers is yet included in the guidelines for differential diagnosis of AD and FTLD. It is assumed that combination of markers might reach ideal accuracy for differentiation [27] , which was not confirmed in our study, except when logistic regression analysis was used allowing for correct classification of 88% FTLD patients using combination of t-tau and p-tau199.
Few studies have investigated CSF biomarkers in age-matched AD and FTLD groups [8, 13, 21, 25, 28] . As positive correlation between CSF p-tau levels and age has been Values presented as Spearman's coefficient (r); AD = Alzheimer's disease, FTLD = frontotemporal dementia, ND = non-demented controls, MMSE = Mini Mental Status Examination, T-tau = total tau, P-tau181 = tau phosphorylated at threonine 181, P-tau199 = tau phosphorylated at serine 199, *r > 0.5 (significant correlation)
shown, it is crucial to mach patients of both conditions by age [29] . In the study by Schoonenboom et al. [7] combination of Aβ42 and p-181 tau reached good differentiation between age-matched AD and FTLD group (with sensitivity of 72% and specificity of 93%). In study by de Jong et al. [8] only combination of t-tau, p-tau181, and neurofilament protein light chain reached adequate diagnostic accuracy with sensitivity of 86% and specificity of 100%; therefore fulfilling criteria for ideal marker. Promising results were reported for p-tau231 by Buerger et al.
[25] Interestingly, satisfying, but not "ideal", results were found for t-tau and Aβ42 in a study with neuropathologically and genetically confirmed cases (with sensitivity of 78.9% and specificity of 96.6%) [30] . During AD progression tau protein can be phosphorylated on almost any hydroxyl group which is shown by detailed inspection of NFT genesis. Thereby, hyperphosphorylation on threonine 181 and 231 occur in pre-NFT phase characterized by punctiform, neurofibrillar intracellular clusters while phosphorylation of tau protein on serine 199 occurs in later phase of AD, so called intra-and extra-neuronal NFT phase [31] . However, according to another study, phosphorylation of p-tau199 appears early in course of the disease; therefore, p-tau199 becomes potentially important marker for early diagnosis of AD [32] . In our previous publication, the values of the same three markers (t-tau, p-tau181 and p-tau199) were analyzed in groups of AD and VaD patients and interestingly, p-tau199 showed better specificity when compared to p-tau181 [32] . So far, tau protein phosphorylated on serine 199 was analyzed only in two studies, but in both patients were not age-matched (AD group statistically older then FTLD group) and statistical analysis and interpretation of the results were incomplete [5, 33] . Relatively higher levels of p-tau199 found in our non-demented group might be due to heterogeneous hyperphosphorylated status found in adult healthy person [34] , but could be also due to inclusion of presymptomatic AD patients in ND group.
To the best of our knowledge, this is the first study to use this combination of CSF biomarkers, and the first to use p-tau199 in differentiating age-matched AD and FTLD patients. Our longterm goal is to increase the number of subjects involved in the study. Longer follow-up period of the patients would lead additionally to better outcome results that may explain falsepositive FTLD cases (e.g. AD cases initially mistaken for FTLD). In conclusion, our study clearly demonstrate that the combination of t-tau and p-tau199 classified correctly 88% of FTLD patients, thus largely satisfying practical requirements.
